Deuterium (2H; D) is a stable and non-radioactive isotope of
hydrogen and it plays an important role in various fields
of science The uniqueness of deuterium (D) over hydrogen (H) is
that C-D bond is shorter and more stable compared
to C-H bond. This unique feature makes it difficult to break C-D
bond and more stable towards the enzymatic
cleavage (CYP450) in in-vivo system.
Recently, approval of the deuterated analogue of tetrabenazine (
Austedo; TEVA) and Deucravacitinib (Sotyktu,
Bristol Myers Squibb) opened an entirely new world in the field
of drug discovery and various Pharmaceutical
companies directed their Research and Development efforts
towards the development of deuterated analogue of
existing non-deuterated drugs to modify drug pharmacokinetics
profile.
Clearsynth has expertise in the development of deuterated analogs
of known drug molecule by systematic analysis of
compounds from literature and selective deuteration at soft
spots to improve the pharmacokinetics (Increase AUC,
increase Half Life, reduce Clearance), mitigate toxic effect of
metabolites, stabilize active metabolite, reduce booster
dose (CYP inhibitors) and improve half-life and bioavailability.
